Hepatitis B
EASL Publishes Revised Clinical Practice Guidelines for Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 17 July 2012 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) recently revised its clinical practice guidelines for the management of patients with chronic hepatitis B virus (HBV) infection. The new recommendations were announced at the International Liver Congress in April in Barcelona and published in the July 2012 Journal of Hepatology. 
FDA Will Review New Dynavax Hepatitis B Virus Vaccine
- Details
- Category: HBV Vaccines
- Published on Wednesday, 27 June 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) has indicated that it will review for approval a new hepatitis B vaccine known as Heplisav.
More than 2 Million People in U.S. May Have Chronic Hepatitis B
- Details
- Category: HBV Epidemiology & Mortality
- Published on Tuesday, 05 June 2012 00:00
- Written by Liz Highleyman
The prevalence of chronic hepatitis B virus (HBV) infection in the U.S. may be as high as 2.2 million -- greater than previously estimated -- with the highest numbers of cases occurring among foreign-born individuals, especially those from Asia and Africa.
Researchers Grow Liver Tissue from Pluripotent Stem Cells
- Details
- Category: Liver Transplant - HBV
- Published on Friday, 22 June 2012 00:00
- Written by Liz Highleyman
Japanese researchers have produced liver-like tissue from induced pluripotent stem cells in the laboratory that can process drugs like a human liver, according to a presentation at the 10th annual meeting of the International Society for Stem Cell Research last week in Yokohama.
Korean Mummy Reveals Hepatitis B Genetic Clues
- Details
- Category: HBV Basic Science
- Published on Wednesday, 30 May 2012 00:00
- Written by Press Release
Genetic analysis of a liver sample from a mummified child found in Korea has revealed a distinct ancient form of a hepatitis B virus C2 genotype now common in Southeast Asia, researchers reported in the May 21, 2012, advance online edition of Hepatology.
HBV Genotype Affects Hepatitis B Disease Progression and Outcomes
- Details
- Category: HBV Disease Progression
- Published on Friday, 22 June 2012 00:00
- Written by Liz Highleyman
Hepatitis B virus (HBV) genotype influences long-term outcomes including viral clearance, according to a Swedish study reported in the May 18, 2012, advance edition of the Journal of Clinical Virology. Genotype C in particular appears to be associated with more aggressive disease.
National Hepatitis Testing Day: Most Infected Are Unaware, All Boomers Should Get HCV Test
- Details
- Category: HBV Testing & Diagnosis
- Published on Friday, 18 May 2012 00:00
- Written by Liz Highleyman
In advance of the National Hepatitis Testing Day on Saturday, May 19, the U.S. Centers for Disease Control and Prevention (CDC) has issued a new recommendation that all Baby Boomers born between 1945 and 1965 should get tested at least once for hepatitis C. Testing Day events will also promote hepatitis B screening, especially for Asian communities. Research shows that a large majority of people with hepatitis B or C do not know they are infected.
Researchers Shed Light on how Hepatitis B Virus Causes Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Wednesday, 20 June 2012 00:00
- Written by Liz Highleyman
Hepatitis B virus (HBV) is more often integrated in liver tumor cells than normal liver tissue cells, and multiple integrations may be linked to more aggressive disease progression and poorer survival, researchers reported in the May 27, 2012 advance online edition of Nature Genetics.
EASL 2012: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
More Articles...
- EASL 2012: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon
- May Is Hepatitis Awareness Month
- EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity
- Complete Coverage of the 2012 International Liver Congress
- EASL 2012: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant
Web Design and Development by